Product Information

ASPIRIN-DIPYRIDAM ER 25-200 MG is a generic product labeled by Amneal Pharmaceuticals LLC, priced at $0.5592 per EA under NDC 65162059606. Its NADAC has been published 499 times since Feb 1, 2017.

FDA first approved this application on Mar 8, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ASPIRIN-DIPYRIDAM ER 25-200 MG

Aspirin and Extended-Release Dipyridamole
$0.5592per EA

Strength

25; 200 mg/1; mg/1

NDC

65162059606

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

ASPIRIN; DIPYRIDAMOLE

Approval Type

Generic (ANDA)

FDA Application

ANDA206392

FDA Approved

3/8/2016

TE Code

AB

On Market Since

3/28/2016

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Decreased Platelet Aggregation
Decreased Platelet Aggregation
Decreased Prostaglandin Production
Nonsteroidal Anti-inflammatory Drug
Platelet Aggregation Inhibitor
Platelet Aggregation Inhibitor

Price Statistics

The NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has been published 499 times since Feb 1, 2017, and over the history we have for it it has declined 86.8%. The table below summarizes its recorded NADAC range and movement.

Current price$0.5592 per EA
All-time high$4.4460 (Feb 13, 2019)
All-time low$0.5561 (Mar 18, 2026)
52-week high$0.6072
52-week low$0.5561
Median price$0.8826
Average price$1.8860
Largest weekly change+44.2% (Apr 21, 2021)
Weeks tracked499
Tracking sinceFeb 1, 2017

Price History

1W

-0.8%

1M

-0.8%

3M

-2.4%

6M

-1.4%

1Y

-5.0%

3Y

-30.4%

5Y

-39.1%

All

-86.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Aspirin and Extended-Release Dipyridamole market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of ASPIRIN-DIPYRIDAM ER 25-200 MG?

The current National Average Drug Acquisition Cost (NADAC) for ASPIRIN-DIPYRIDAM ER 25-200 MG, manufactured by Amneal Pharmaceuticals LLC, is $0.5592 per EA (NDC 65162059606), effective Aug 19, 2026.

How has the price of ASPIRIN-DIPYRIDAM ER 25-200 MG changed over time?

Over the history we have for it, the NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has declined 86.8%. It has been tracked across 499 weekly CMS publications since Feb 1, 2017.

What are the highest and lowest recorded NADAC prices for ASPIRIN-DIPYRIDAM ER 25-200 MG?

Since Feb 1, 2017, the NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has ranged from a low of $0.5561 (Mar 18, 2026) to a high of $4.4460 (Feb 13, 2019), with a median of $0.8826 per EA.

Are there cheaper alternatives to ASPIRIN-DIPYRIDAM ER 25-200 MG?

No other NADAC-published product currently shares the active ingredient and strength of ASPIRIN-DIPYRIDAM ER 25-200 MG in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures ASPIRIN-DIPYRIDAM ER 25-200 MG?

ASPIRIN-DIPYRIDAM ER 25-200 MG (NDC 65162059606) is labeled by Amneal Pharmaceuticals LLC, and CMS classifies it as a generic product.